浸润性乳腺癌患者高频超声声像图特征与免疫组化关系的研究

High frequency ultrasonographic properties and immunohistochemistry findings in invasive breast cancer

目的:探讨浸润性乳腺癌患者高频超声声像图特征与免疫组化的关系。方法:收集在芜湖市中医医院接受手术治疗的44例浸润性乳腺癌患者的临床资料,分析总结其超声声像图特征与免疫组化的关系。结果:ER、PR阳性表达者在边缘毛刺征组和后方回声衰减组高于ER、PR阴性表达者,两组差异均有统计学意义(P<0.05);在微小钙化组、血流分级组、肿块大小组及腋窝淋巴结组差异无统计学意义(P>0.05)。C-erbB-2阳性表达者在边缘毛刺征组和后方回声衰减组低于C-erbB-2阴性表达者,两组差异有统计学意义(P<0.05);C-erbB-2阳性表达者在肿块内部有微小钙化组和腋窝淋巴结有转移组高于C-erbB-2阴性表达者,两组差异有统计学意义(P<0.05);在血流分级组、肿块大小组差异无统计学意义(P>0.05)。Ki-67阳性表达者在各个超声声像图特征分组中差异均无统计学意义。结论:高频超声声像图特征中边缘毛刺征、后方回声衰减、内部微小钙化及腋窝淋巴结转移在一定程度上可以反映ER、PR、C-erbB-2的表达情况。

Objective:To investigate the relationship between high frequency ultrasonographic imaging property and immunohistochemistry findings in invasive breast cancer.Methods:The clinical data were obtained from 44 cases of invasive breast cancer surgically treated in our hospital,and reviewed for the high frequency ultrasonographic demonstration and pathological results of immunohistochemistry.Results:Higher positive expression of ER and PR and posterior echo attenuation were seen in the lesion with marginal "burr" sign compared to negative expression of ER and PR(P<0.05),yet the difference was insignificant concerning microcalcification,blood flow grading,mass size and involvement of axillary lymph nodes(P>0.05).C-erbB-2 was highly positively expressed and posterior echo attenuation was more frequent in cancer tissues as compared with negatively expressed C-erbB-2(P<0.05).More microcalcification and axillary lymph node involvement were seen in cases with positive expression of C-erbB-2(P<0.05).However,there was no statistical difference pertinent to blood flow grading and mass size as well as ultrasonographic imaging in cases with positively expressed Ki-67(P>0.05).Conclusion:High frequency ultrasonographic demonstration by "burr" sign at the peripheral lesion,posterior echo attenuation,internal microcalcification and axillary lymph node involvement may to a certain extent predict the expression of ER,PR and C-erbB-2 in patients with invasive breast cancer.